NASDAQ: GRFS
Grifols Sa Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their GRFS stock forecasts and price targets.

Forecast return on equity

Is GRFS forecast to generate an efficient return?

Company
18.27%
Industry
9.19%
Market
167.6%
GRFS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GRFS forecast to generate an efficient return on assets?

Company
4.89%
Industry
26.66%
GRFS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GRFS earnings growth forecast

How is GRFS forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
26.59%
Industry
37.94%
Market
31.05%
GRFS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
GRFS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
GRFS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

GRFS revenue growth forecast

How is GRFS forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
0.58%
Industry
7.23%
Market
13.43%
GRFS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GRFS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GRFS vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
GRFS$7.80N/AN/A
OGN$13.78$14.00+1.60%Hold
AMRN$13.63$13.00-4.62%Strong Sell
SCLX$5.42N/AN/A
NSRX$3.74$18.00+381.93%Buy

Grifols Sa Stock Forecast FAQ

What is GRFS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GRFS) forecast ROE is 18.27%, which is considered weak.

If you're new to stock investing, here's how to buy Grifols Sa stock.

What is GRFS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GRFS) forecast ROA is 4.89%, which is lower than the forecast US Drug Manufacturers - General industry average of 26.66%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.